Related Experiment Video

Updated: Aug 14, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

17.0K

PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes

Ancha Baranova1

  • 1Center for Biomedical Genomics and Bioinformatics, Molecular and Microbiology Department, College of Science, George Mason University, Fairfax, VA 22031, USA.

PPAR Research
|July 23, 2008
PubMed

Insights

Peroxisome proliferator-activated receptor (PPAR) agonists may impact breast cancer risk in diabetic patients. This review explores how PPAR ligands influence breast carcinoma initiation and progression pathways.

Area of Science:

  • Endocrinology
  • Oncology
  • Metabolic Syndrome Research

Background:

  • Nuclear receptors of the PPAR family regulate energy homeostasis and insulin resistance.
  • PPAR agonists are investigated for metabolic syndrome treatment and secondary complication prevention.
  • PPAR ligands at high doses affect breast carcinoma cell proliferation and apoptosis.

Purpose of the Study:

  • To review the potential influence of chemical PPAR ligands on breast carcinoma molecular pathways.
  • To focus on PPARgamma agonists, specifically thiazolidinediones (TZDs).
  • To explore how PPAR agonists might alter breast cancer risk in diabetic patients.

Main Methods:

  • Literature review summarizing existing research on PPAR ligands and breast carcinoma.
  • Analysis of molecular pathways involved in breast cancer initiation and progression.
  • Emphasis on studies involving PPARgamma agonists (TZDs).

Main Results:

  • PPAR agonists can influence breast carcinoma cell behavior.
  • Diabetic patients on PPAR agonists might experience altered breast cancer risk.
  • Potential modifications in breast lesion incidence and progression rates are suggested.

Conclusions:

  • Chemical PPAR ligands may affect the molecular pathways of breast carcinoma initiation and progression.
  • Further investigation is needed to clarify the impact of PPAR agonists on breast cancer risk, especially in diabetic populations.
  • Thiazolidinediones (TZDs) warrant specific attention due to their prominent role as PPARgamma agonists.

More Related Videos

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module10:39

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module

Published on: June 18, 2015

13.8K
Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.1K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...